Revamped Novartis In Good Shape At 3Q Ahead Of CEO Succession

 
• By Sten Stovall

Novartis beat third-quarter forecasts, flagged its strengthening drug portfolio, and said its CEO transition remains on track for February 2018, but a decision on its eye care division awaits.

Successive Biz concept
Novartis' Outgoing CEO Says Handover On Track, Company Advancing • Source: Shutterstock

More from Earnings

More from Business